

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-49. (Cancelled)

50. (Previously Presented) A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a therapeutic agent dispersed in a polymer matrix, wherein said cytostatic amount of said therapeutic agent inhibits a vascular smooth muscle cell activity without killing the cell, and wherein said therapeutic agent is a TGF-beta production or activation stimulator, TGF-beta, tamoxifen, a nuclear enzyme DNA topoisomerase II inhibitor, a DNA polymerase inhibitor, an RNA polymerase inhibitor, an adenylyl guanylyl cyclase inhibitor, a superoxide dismutase inhibitor, a terminal deoxynucleotidyl-transferase, a reverse transcriptase, lovastatin, vinblastin, cytochalasins, taxol, taxotere, trichothecene, *Pseudomonas exotoxin*, a chemotactic factor inhibitor, a chemotactic factor receptor inhibitor, an intracellular cytoskeletal protein inhibitor, a caffeic acid derivative, nilvadipine, a steroid hormone, sphingosine, somatostatin, or N-ethylmaleimide.

51. (Cancelled).

52. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises placement of a stent.

53. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises angioplasty.

54. (Previously presented) The method of claim 50, wherein the locally administering comprises administering the cytostatic amount of the therapeutic agent directly to vascular smooth muscle tissue.

55. (Previously presented) The method of claim 50, wherein the release of the cytostatic amount of the therapeutic agent from the dosage form occurs during or after the vascular surgical procedure.

56-57. (Cancelled).

58. (Previously presented) The method of claim 50, wherein the therapeutic agent comprises taxol or taxotere.

59. (Previously Presented) The method of claim 50, wherein the sustained release dosage form is a microparticulate.

60-65. (Cancelled).

66. (New) The method of claim 50, wherein locally administering comprises administering the biocompatible, non-biodegradable sustained release dosage form intraluminally.

67. (New) The method of claim 50, wherein locally administering comprises delivering a cytostatic amount of the biocompatible, non-biodegradable sustained release dosage form to the proximal 6 to 9 cell layers of the tunica media smooth muscle cells lining the lumen of a vessel.